1.Current Status on Studies of Bereaved Family in Korea: Research Trends for 1994-2013.
Korean Journal of Hospice and Palliative Care 2014;17(3):134-141
PURPOSE: This study was conducted to identify the current status of studies of bereaved families in Korea. METHODS: We reviewed 97 studies of bereaved families, which were published between 1994 and 2013 in Korea. The studies were classified in three groups according to time, subjects, and topic. RESULTS: First, the number of bereaved family-related studies has increased since 2010. Second, most studies focused on the whole family, and middle-age widows were also popular subjects. Third, the most popular topic was a relationship between certain variables. CONCLUSION: First, variables and their relations among themselves should be approached through an integrated study. Second, a systematic review is needed to assess the effects of interventions on the bereaved. Third, a qualitative research method is needed to broaden and deepen our understanding about the middle-age widowers, parents who lost their children and children who lost their parents.
Bereavement
;
Child
;
Humans
;
Korea
;
Parents
;
Qualitative Research
;
Review Literature as Topic
;
Widowhood
2.Extradural Spinal Lymphoplasmacyte-Rich Meningioma in the Thoracic Spine: A Case Report and Literature Review
Eun Hye SEO ; Jang Gyu CHA ; Yu Sung YOON ; Ah Rim MOON
Journal of the Korean Radiological Society 2022;83(4):924-930
Most spinal meningiomas have an intradural or partly extradural location. The meningothelial origin is the most common pathologic type of spinal meningioma. Pure extradural spinal meningiomas are not common, and lymphoplasmacyte-rich meningioma (LPRM) is very rare. We report a case of isolated extradural spinal meningioma in the thoracic spine that was pathologically confirmed as LPRM.
3.Percutaneous Placement of Self-Expandable Metallic Stents in Patients with Obstructive Jaundice Secondary to Metastatic Gastric Cancer after Gastrectomy.
Hyun Pyo HONG ; Tae Seok SEO ; In Ho CHA ; Jung Rim YU ; Young Jae MOK ; Joo Hyeong OH ; Se Hwan KWON ; Sam Soo KIM ; Seung Kwon KIM
Korean Journal of Radiology 2013;14(5):789-796
OBJECTIVE: To evaluate the outcomes of patients undergoing percutaneous placements of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy. MATERIALS AND METHODS: Fifty patients (mean age, 62.4 years; range, 27-86 years) who underwent percutaneous placements of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy were included. The technical success rate, clinical success rate, complication rate, stent patency, patient survival and factors associated with stent patency were being evaluated. RESULTS: The median interval between the gastrectomy and stent placement was 23.1 months (range, 3.9-94.6 months). The 50 patients received a total of 65 stents without any major procedure-related complications. Technical success was achieved in all patients. The mean total serum bilirubin level, which had been 7.19 mg/dL +/- 6.8 before stent insertion, decreased to 4.58 mg/dL +/- 5.4 during the first week of follow-up (p < 0.001). Clinical success was achieved in 42 patients (84%). Percutaneous transhepatic biliary drainage catheters were removed from 45 patients (90%). Infectious complications were noted in two patients (4%), and stent malfunction occurred in seven patients (14%). The median stent patency was 233 +/- 99 days, and the median patient survival was 179 +/- 83 days. Total serum bilirubin level after stenting was an independent factor for stent patency (p = 0.009). CONCLUSION: Percutaneous transhepatic placement of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy is a technically feasible and clinically effective palliative procedure.
Adult
;
Aged
;
Aged, 80 and over
;
Bile Duct Neoplasms/complications/secondary/*surgery
;
Bile Ducts, Extrahepatic/*surgery
;
Female
;
Follow-Up Studies
;
Gastrectomy
;
Humans
;
Jaundice, Obstructive/diagnosis/etiology/*surgery
;
Male
;
Middle Aged
;
Prosthesis Design
;
Retrospective Studies
;
*Stents
;
Stomach Neoplasms/*complications/secondary/surgery
;
Treatment Outcome
4.Effect of Abciximab on the Levels of Circulating Microparticles in Patients with Acute Myocardial Infarction Treated by Primary Angioplasty.
Jung Joon CHA ; Jong Youn KIM ; Eui Young CHOI ; Pil Ki MIN ; Minhee CHO ; Da Lyung LEE ; Sung Yu HONG ; Young Won YOON ; Byoung Kwon LEE ; Bum Kee HONG ; Se Joong RIM ; Hyuck Moon KWON
Korean Circulation Journal 2013;43(9):600-606
BACKGROUND AND OBJECTIVES: We investigated the effect of the additional use of abciximab during percutaneous coronary intervention (PCI) on the level of procoagulant microparticles (MPs) in patients with ST-segment elevation myocardial infarction (STEMI) who had undergone primary PCI. SUBJECTS AND METHODS: In this study, we studied 86 patients with STEMI (72 men, age 58+/-13) who had undergone primary PCI. The decision to administer abciximab immediately prior to PCI was left to the discretion of the operator. Blood samples for analysis of MPs were obtained from the femoral artery before and after PCI. MPs with procoagulant potential were measured using a commercial kit. The cellular origins of MPs were determined by antigenic capture with specific antibodies. RESULTS: Procoagulant MPs captured onto annexin V were not changed significantly after PCI {13.4+/-13.2 nM vs. 13.2+/-16.1 nM phosphatidylserine equivalent (PS eq), p=0.479}. Abciximab was used in 30 of 86 patients (35%) immediately prior to PCI. In patients who had undergone PCI without abciximab, no significant change in the level of MPs was observed after PCI. However, in the abciximab group, the level of circulating MPs was significantly decreased after PCI (12.0+/-10.7 nM vs. 7.8+/-11.7 nM PS eq, p=0.018). Levels of endothelial- and platelet-derived MPs also showed a significant reduction after PCI in the abciximab group. CONCLUSION: Primary PCI with additional abciximab significantly reduced the level of procoagulant MPs regardless of their cellular origins in patients with STEMI.
Angioplasty
;
Annexin A5
;
Antibodies, Monoclonal
;
Cell-Derived Microparticles
;
Femoral Artery
;
Humans
;
Immunoglobulin Fab Fragments
;
Male
;
Myocardial Infarction
;
Percutaneous Coronary Intervention
;
Platelet Aggregation Inhibitors